Impact of graft sources on immune reconstitution and survival outcomes following allogeneic stem cell transplantation. 2020

Taiki Ando, and Takayoshi Tachibana, and Masatsugu Tanaka, and Taisei Suzuki, and Yasufumi Ishiyama, and Satoshi Koyama, and Eriko Ogusa, and Ayumi Numata, and Kenji Matsumoto, and Heiwa Kanamori, and Hideaki Nakajima
Department of Hematology, Kanagawa Cancer Centre, Yokohama, Japan.

We evaluated the kinetics of immune reconstitution (IR) after allogeneic hematopoietic cell transplantation (HSCT) and analyzed the clinical effect of IR on posttransplant outcomes. Absolute lymphocyte and its subset counts were measured using flow cytometry on days 28, 100, 180, 365, and 730 after transplantation in 358 adult patients who underwent HSCT between 2009 and 2017. On day 100 after HSCT, 310 surviving patients were analyzed. Bone marrow transplantation (BMT), peripheral blood stem cell transplantation (PBSCT), and cord blood transplantation (CBT) were performed in 119, 55, and 136 patients, respectively. Mature B-cell and differentiated natural killer (NK) cell subset counts significantly increased after CBT. The 2-year overall survival (OS), nonrelapse mortality (NRM), cumulative incidence of relapse, and chronic GVHD in BMT, PBSCT, and CBT were 62%, 67%, and 76% (P = .021); 17%, 17%, and 13% (P = .82); 33%, 40%, and 27% (P = .063); and 43%, 45%, and 28% (P = .025), respectively. Multivariate analysis showed that higher CD16+CD57- NK cell counts correlated with lower disease relapse, whereas higher CD20+ B-cell counts correlated with lower NRM. OS-favoring factors were higher CD16+CD57- NK cell count (hazard ratio, 0.36; 95% confidence interval, 0.22-0.60; P < .001) and CD20+ B-cell count (hazard ratio, 0.53; 95% confidence interval, 0.30-0.93; P < .001) and lower Disease Risk/HCT-Specific Comorbidity index score. Collective contribution of graft source-specific and event-related immune reconstitution might yield better posttransplant outcomes in CBT.

UI MeSH Term Description Entries
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D006086 Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. Graft-Versus-Host Disease,Homologous Wasting Disease,Runt Disease,Graft-vs-Host Disease,Disease, Graft-Versus-Host,Disease, Graft-vs-Host,Disease, Homologous Wasting,Disease, Runt,Diseases, Graft-Versus-Host,Diseases, Graft-vs-Host,Graft Versus Host Disease,Graft-Versus-Host Diseases,Graft-vs-Host Diseases
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000074243 Immune Reconstitution Regeneration of normal immune function after immune depleting procedures or infections (e.g., HEMATOPOIETIC STEM CELL TRANSPLANTATION). Delayed and incomplete reconstitution of the ADAPTIVE IMMUNE system in particular involving T-CELLS is associated with increase or relapse of infection. Immune Regeneration,Immune Restoration
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D014184 Transplantation, Homologous Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals. Transplantation, Allogeneic,Allogeneic Grafting,Allogeneic Transplantation,Allografting,Homografting,Homologous Transplantation,Grafting, Allogeneic
D016017 Odds Ratio The ratio of two odds. The exposure-odds ratio for case control data is the ratio of the odds in favor of exposure among cases to the odds in favor of exposure among noncases. The disease-odds ratio for a cohort or cross section is the ratio of the odds in favor of disease among the exposed to the odds in favor of disease among the unexposed. The prevalence-odds ratio refers to an odds ratio derived cross-sectionally from studies of prevalent cases. Cross-Product Ratio,Risk Ratio,Relative Odds,Cross Product Ratio,Cross-Product Ratios,Odds Ratios,Odds, Relative,Ratio, Cross-Product,Ratio, Risk,Ratios, Cross-Product,Ratios, Risk,Risk Ratios
D016019 Survival Analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function. Analysis, Survival,Analyses, Survival,Survival Analyses
D016026 Bone Marrow Transplantation The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION. Bone Marrow Cell Transplantation,Grafting, Bone Marrow,Transplantation, Bone Marrow,Transplantation, Bone Marrow Cell,Bone Marrow Grafting
D016131 Lymphocyte Subsets A classification of lymphocytes based on structurally or functionally different populations of cells. Lymphocyte Subpopulations,Lymphocyte Subpopulation,Lymphocyte Subset,Subpopulation, Lymphocyte,Subpopulations, Lymphocyte,Subset, Lymphocyte,Subsets, Lymphocyte

Related Publications

Taiki Ando, and Takayoshi Tachibana, and Masatsugu Tanaka, and Taisei Suzuki, and Yasufumi Ishiyama, and Satoshi Koyama, and Eriko Ogusa, and Ayumi Numata, and Kenji Matsumoto, and Heiwa Kanamori, and Hideaki Nakajima
November 2016, Virulence,
Taiki Ando, and Takayoshi Tachibana, and Masatsugu Tanaka, and Taisei Suzuki, and Yasufumi Ishiyama, and Satoshi Koyama, and Eriko Ogusa, and Ayumi Numata, and Kenji Matsumoto, and Heiwa Kanamori, and Hideaki Nakajima
January 2005, Haematologica,
Taiki Ando, and Takayoshi Tachibana, and Masatsugu Tanaka, and Taisei Suzuki, and Yasufumi Ishiyama, and Satoshi Koyama, and Eriko Ogusa, and Ayumi Numata, and Kenji Matsumoto, and Heiwa Kanamori, and Hideaki Nakajima
August 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
Taiki Ando, and Takayoshi Tachibana, and Masatsugu Tanaka, and Taisei Suzuki, and Yasufumi Ishiyama, and Satoshi Koyama, and Eriko Ogusa, and Ayumi Numata, and Kenji Matsumoto, and Heiwa Kanamori, and Hideaki Nakajima
July 2019, Expert review of clinical immunology,
Taiki Ando, and Takayoshi Tachibana, and Masatsugu Tanaka, and Taisei Suzuki, and Yasufumi Ishiyama, and Satoshi Koyama, and Eriko Ogusa, and Ayumi Numata, and Kenji Matsumoto, and Heiwa Kanamori, and Hideaki Nakajima
January 2005, Haematologica,
Taiki Ando, and Takayoshi Tachibana, and Masatsugu Tanaka, and Taisei Suzuki, and Yasufumi Ishiyama, and Satoshi Koyama, and Eriko Ogusa, and Ayumi Numata, and Kenji Matsumoto, and Heiwa Kanamori, and Hideaki Nakajima
June 2004, Leukemia & lymphoma,
Taiki Ando, and Takayoshi Tachibana, and Masatsugu Tanaka, and Taisei Suzuki, and Yasufumi Ishiyama, and Satoshi Koyama, and Eriko Ogusa, and Ayumi Numata, and Kenji Matsumoto, and Heiwa Kanamori, and Hideaki Nakajima
January 2015, Hematology. American Society of Hematology. Education Program,
Taiki Ando, and Takayoshi Tachibana, and Masatsugu Tanaka, and Taisei Suzuki, and Yasufumi Ishiyama, and Satoshi Koyama, and Eriko Ogusa, and Ayumi Numata, and Kenji Matsumoto, and Heiwa Kanamori, and Hideaki Nakajima
January 2016, Frontiers in immunology,
Taiki Ando, and Takayoshi Tachibana, and Masatsugu Tanaka, and Taisei Suzuki, and Yasufumi Ishiyama, and Satoshi Koyama, and Eriko Ogusa, and Ayumi Numata, and Kenji Matsumoto, and Heiwa Kanamori, and Hideaki Nakajima
October 2008, Zhongguo shi yan xue ye xue za zhi,
Taiki Ando, and Takayoshi Tachibana, and Masatsugu Tanaka, and Taisei Suzuki, and Yasufumi Ishiyama, and Satoshi Koyama, and Eriko Ogusa, and Ayumi Numata, and Kenji Matsumoto, and Heiwa Kanamori, and Hideaki Nakajima
February 2004, British journal of haematology,
Copied contents to your clipboard!